Supervisor Database Search
Guidance for ICAT Supervisors
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.
You can read about the ICAT supervisor selection process and eligibility criteria below:
Terms of reference/guide to supervising ICAT Fellows.
You can read the terms of reference for supervisors actively supervising ICAT Fellows below:
Supervisor Database
Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameDr Arun Kumar
Veterinary Biosciences
University College Dublin
Webpage:people.ucd.ie
Email hidden; Javascript is required.
- physiology and non-communicable disease
- cancer/oncology
- bioengineering/medical devices
- comparative medicine
- Other
Network Pharmacology
- Medicine
- Veterinary Medicine
- Cardiology
- Health Informatics
- Neurophysiology
- Pharmacology
- Physiology
- Vascular Medicine
My research group Stemcology is dedicated to understand the therapeutic potential of stem cell factors and small molecules for cardiovascular and neurovascular complications. The focus of my work is to evaluate the detailed pharmacological mechanisms (using network pharmacology and in-vitro assays) of these potential therapeutics with an aim to provide evidence based precision medicines, which will not only have optimal efficacy but with minimal off target effects.
Network pharmacology is an interdisciplinary approach that combines elements of systems biology, bioinformatics, and pharmacology to understand the complex interactions between drugs, targets, and diseases within biological networks. It uses computational methods to analyse data sets, including molecular, and clinical information, to gain insights into drug actions and disease mechanisms.
In addition to therapeutic development of small molecules, my group is also involved in developing medical devices for applications in neurosurgery and autonomic nervous system evaluation.
I have adopted sustainable research publication practice and hence exclusively publish in open and free access domains for wider reach of my scholarly work.
My list of publications is available from https://shorturl.at/qtwH5
The research projects in my group employ network pharmacology approaches to identify novel therapeutic targets and drug candidates for cardiovascular and neurovascular diseases. By integrating diverse omics data and constructing disease-specific biological networks, the study aims to discover key nodes and prioritise potential drug targets. Utilising in silco methods, identified compounds will be screened for their potential therapeutic effects, followed by validation through in vitro and in vivo experiments. At every stage of the project, integration of clinical data will be performed using in-house algorithms to validate the relevance of the findings in human subjects, contributing to the advancement of personalised medicine in the treatment of cardiovascular and neurovascular disorders. Additionally, ethical considerations and safety assessments will be addressed throughout the research, ensuring the responsible development of novel therapeutic interventions.
Current research pipeline (projects) include:
STGY5308: Clot buster, Anticoagulant - for the treatment of thrombotic disorders.
STGY2626: Mucolytic – Aimed to dissolve mucus and alleviate conditions associated with excessive mucus production.
STGY3571: Alzheimer's dementia - with a focus on neuroprotection and cognitive improvement.
STGY7108: Hepatocellular carcinoma.
STGY6253: Glioblastoma multiforme.
STGY8062: Wound healing and scar reduction - offering promising prospects for regenerative dermatology.
Medical devices: Valveless shunt for surgical management of hydrocephalus and AI device to assess autonomic balance.